TITLE

Guidelines for the Treatment of Preoperative Anaemia with Epoetin

AUTHOR(S)
Goodnough, L.T.
PUB. DATE
September 1998
SOURCE
BioDrugs;1998, Vol. 10 Issue 3, p183
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recombinant human erythropoietin (epoetin) has been approved for use in patients undergoing autologous blood donation (ABD) in Japan, the European Union and Canada since 1993, 1994 and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1996. Early clinical trials of epoetin therapy in the setting of ABD have provided important information with respect to clinical safety, dose and erythropoietic response. Later trials of perisurgical epoetin therapy without ABD provided data on efficacy (i.e. reduced allogeneic blood exposure) that led to approval of epoetin in this setting. However, the epoetin doses (300 U/kg subcutaneously × 14 days) used in these trials, and their subsequent inclusion in labelling for the use of this product, are costly to administer. A recent study has indicated that weekly administration of epoetin 600 U/kg over 4 weeks is just as effective but less costly than a daily regimen over 2 weeks. The most cost-effective regimen that has been shown to minimise allogeneic exposure is preoperative epoetin therapy with 600 U/kg/ week × 2 plus 300 U/kg on the day of surgery, coupled with acute normovolaemic haemodilution in patients undergoing radical retropubic prostatectomy. A similar regimen of epoetin therapy in patients undergoing coronary artery bypass grafting (2500 U/kg in divided doses over 2 weeks preoperatively) coupled with ‘blood pooling’, has also been described. ‘Low dose’ epoetin therapy coupled with acute normovolaemic haemodilution is cost-equivalent to the predonation of 3 autologous blood units, and may replace this strategy as a standard of care in the elective surgical setting.
ACCESSION #
9522796

 

Related Articles

  • Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia. Fjornes, T. // Journal of Oncology Pharmacy Practice;Mar1999, Vol. 5 Issue 1, p22 

    Objective. Anemia is commonly observed in tumor patients and may be worsened by the concomitant administration of chemotherapy with platinum. Recombinant human erythropoietin (rhEPO) is able to improve the chemotherapy-associated anemia and the quality of life in patients with solid tumors. The...

  • Novel erythropoiesis-stimulating protein. Joy, Melanie S. // Formulary;Jan2001, Vol. 36 Issue 1, p19 

    Recombinant human erythropoietin (r-HuEPO) is the gold standard for treatment of anemia related to chronic renal failure or cancer chemotherapy. However, because of its short half-life, r-HuEPO must be administered two to three times weekly in most patients. Novel erythropoiesis-stimulating...

  • Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. Stevens, Marion E.; Summerfield, Geoffrey P.; Hall, Alan A.; Beck, Carol A.; Harding, Anthony J.; Cove-Smith, J. Rodney; Paterson, Andrew D. // BMJ: British Medical Journal (International Edition);2/22/92, Vol. 304 Issue 6825, p474 

    Assesses the cost benefits of low dose subcutaneous recombinant human erythropoietin in anemia of end stage renal disease in Great Britain. Symptoms of anemic end stage renal disease; Administration of continuous ambulatory peritoneal dialysis; Maintenance of hemoglobin concentration with...

  • Erythropoetin accelerates hematocrit recovery in post-surgical anemia. Atabek, Umur; Alvarez, Ronald; al, et // American Surgeon;Jan1995, Vol. 61 Issue 1, p74 

    Studies the role of recombinant human erythropoietin (RHE) on the treatment of post-surgical anemia in Jehovah's Witness patients refusing transfusion. Changes in hematocrit levels; Observation of effects; Comparison with the use of standard treatments with iron, nutritional support and other...

  • Current state and perspectives on erythropoietin production. Lee, Jae; Ha, Tae; Lee, Seung; Lee, Gyun // Applied Microbiology & Biotechnology;Sep2012, Vol. 95 Issue 6, p1405 

    Erythropoietin is a major regulator of erythropoiesis which maintains the body's red blood cell mass and tissue oxygenation at an optimum level. Recombinant human erythropoietin (rhEPO), which is a widely used therapeutic agent for the treatment of anemia and which represents one of the largest...

  • Erythropoiesis stimulating agents: approaches to modulate activity. Sinclair, Angus M. // Biologics: Targets & Therapy;2013, Vol. 7, p161 

    Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may...

  • Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. Miyake, Makito; Goodison, Steve; Lawton, Adrienne; Ge Zhang; Gomes-Giacoia, Evan; Rosser, Charles J. // Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1 

    Background: Erythropoietin (EPO) provides an alternative to transfusion for increasing red blood cell mass and treating anemia in cancer patients. However, recent studies have reported increased adverse events and/or reduced survival in patients receiving both EPO and chemotherapy, potentially...

  • How important is transfusion avoidance in 2013? Macdougall, Iain C.; Obrador, Gregorio T. // Nephrology Dialysis Transplantation;May2013, Vol. 28 Issue 5, p1092 

    Prior to the advent of recombinant erythropoietin in the late-1980s, blood transfusions were the mainstay of anaemia management in patients with end-stage renal failure, many of whom required “top-up” transfusions every 2 to 4 weeks to relieve the debilitating symptoms of severe...

  • Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. Tatarelli, Caterina; Piccioni, Anna; Maurillo, Luca; Naso, Virginia; Battistini, Roberta; D'Andrea, Mariella; Criscuolo, Marianna; Nobile, Carolina; Villivà, Nicoletta; Mancini, Stefano; Neri, Benedetta; Breccia, Massimo; Fenu, Susanna; Buccisano, Francesco; Voso, Maria; Latagliata, Roberto; Aloe Spiriti, Maria // Annals of Hematology;Aug2014, Vol. 93 Issue 8, p1413 

    Myelodysplastic syndromes (MDS) are common in elderly patients. Recombinant human erythro-poietin (rHuEPO) has been widely used to treat anemia in lower risk MDS patients, but few data are known about rHuEPO treatment in the very elderly patient group. In order to investigate the role of rHuEPO...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics